No Data
No Data
LifeSci Capital Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $12
Buy Rating Affirmed for TScan Therapeutics Amid Positive Developments in TCR-T Cell Therapy Space
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
Express News | TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39TH Annual Meeting
TScan Therapeutics Director Buys $26,450 in Company Stock
TScan Therapeutics to Participate in Upcoming Investor Conferences
No Data
No Data